- Home
- GRRR vs NBP Comparison
GRRR vs NBP Comparison
Compare GRRR & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GRRR | NBP |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | United Kingdom | United States |
| Employees | N/A | 32 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 323.0M | 379.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GRRR | NBP |
|---|---|---|
| Price | $14.40 | $2.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 488.6K | ★ 945.0K |
| Earning Date | 03-02-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $69.35 | N/A |
| Revenue Next Year | $85.38 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.04 | $2.10 |
| 52 Week High | $27.90 | $5.19 |
Technical Indicators
Market Signals| Indicator | GRRR | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 71.21 | 43.60 |
| Support Level | $12.10 | $2.27 |
| Resistance Level | $15.84 | $3.80 |
| Average True Range (ATR) | 0.76 | 0.17 |
| MACD | 0.43 | 0.05 |
| Stochastic Oscillator | 75.04 | 49.39 |
Price Performance
Historical ComparisonAbout GRRR Gorilla Technology Group Inc.
Gorilla Technology Group Inc is engaged in providing information, software, and data processing services. It is a provider of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology (OT) security solutions and services. Its reportable segments are video IoT and security convergence and Other segments.
About NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. It integrates scientific discovery with strategic planning and project management to move therapies from research toward potential patient use. Its pipeline includes Givastomig, VIS-101, Ragistomig and Uliledlimab.